Position in TNGX
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$11,902,119
+$4,760,847 QoQ
Shares Held
380,746
+11.5% QoQ
Ownership
0.226%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#71
of 247 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 88%
Shared 0%
None 12%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CONGRESS ASSET MANAGEMENT CO holds $715,705,658 across 14 Biotechnology names. TNGX ranks #7 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
659,911 | $208,591,267 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
2,600,123 | $142,850,757 | |
| 3 | VCEL |
Vericel Corp
|
2,916,295 | $129,745,964 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
1,229,106 | $96,202,126 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
265,701 | $79,983,972 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
40,134 | $14,916,603 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
This page
|
380,746 | $11,902,119 | |
| 8 | RLAY |
Relay Therapeutics, Inc.
|
626,141 | $11,715,098 |
All Filings in TNGX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,902,119 | 380,746 | Shares | Sole | 2026-07-07 | |
| 2026-03-31 | $7,141,272 | 341,361 | Shares | Sole | 2026-04-14 | |
| 2025-12-31 | $2,078,804 | 234,628 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $1,916,208 | 228,120 | Shares | Sole | 2025-10-10 | |
| 2025-06-30 | $1,163,233 | 227,194 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $311,484 | 227,361 | Shares | Sole | 2025-04-11 | |
| 2024-12-31 | $704,486 | 227,989 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $1,609,839 | 209,070 | Shares | Sole | 2024-10-28 | |
| 2024-06-30 | $1,811,838 | 211,170 | Shares | Sole | 2024-08-02 | |
| No filing history on record for this holder in this stock. | ||||||